Molina Healthcare is down as the market digests renewed analyst skepticism around the company’s earnings recovery path, with price-target reductions and commentary pointing to a 2026 outlook that leaves little room for upside. The broader concern is that medical cost trends and contract-specific execution risks can keep earnings power under pressure even after the recent reset in expectations. (investing.com)

The recent stock weakness remains closely linked to Molina’s sharply reduced 2026 profit expectations and the view that utilization and medical cost inflation are outrunning premium-rate adequacy in key lines. Investors are treating 2026 as a high-uncertainty “trough/bridge” period where even meeting reduced targets depends on stabilization in utilization and clean execution on major state program contracts. (news.bloomberglaw.com)

Near-term catalysts include incremental analyst revisions, any additional guidance commentary, and evidence that medical cost ratios are normalizing. Separately, credit/capital optics remain a swing factor after the credit outlook was previously revised to negative on capital and leverage-related concerns—something that can influence sentiment when earnings visibility is already fragile. (investing.com)